Neurocrine Biosciences, Inc. (NBIX)

Over the past six months, Neurocrine Biosciences' stock (NBIX) has experienced fluctuations, with a 52-week range between $84.23 and $160.18. As of early March 2026, the share price was around $133.44, representing an increase of 17.21% over the previous year, but recent declines show a -9.54% change over the past six months and -9.37% year-to-date as of late March 2026. Key events impacting the stock price include Q4 and Full-Year 2025 financial results, where Neurocrine Biosciences reported fourth-quarter earnings that exceeded analyst expectations. Despite strong Q4 2025 performance, the company's conservative 2026 guidance for INGREZZA net product sales led to the stock remaining largely unchanged after the earnings release. Analyst sentiment in January 2026 provided a mixed but generally positive outlook, with an average 12-month price target of $179.83. Neurocrine Biosciences management participated in several investor conferences, providing updates on commercial performance and pipeline development. An amendment to its collaboration with Takeda granted Neurocrine exclusive worldwide rights to osavampator, and a global licensing agreement with Pharmaron and collaboration with TransThera Sciences for NLRP3 inhibitors outside Greater China was also announced.

Information specifically detailing demand seasonality for Neurocrine Biosciences' products and services is not readily available in the provided search results. However, historical data for NBIX stock performance indicates some seasonality, with January being the strongest month and September tending to be the weakest month. It is important to note that stock seasonality does not directly equate to product demand seasonality, which is typically driven by disease prevalence, diagnosis rates, treatment guidelines, and market access rather than seasonal consumer trends.

Neurocrine Biosciences, Inc. (NBIX) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and commercializing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's portfolio includes FDA-approved treatments like INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, Orilissa for endometriosis, Oriahnn for heavy menstrual bleeding associated with uterine fibroids, and CRENESSITY for congenital adrenal hyperplasia (CAH). Neurocrine Biosciences also maintains a robust pipeline with multiple compounds in mid-to-late-phase clinical development, targeting conditions such as Parkinson's disease, Tourette syndrome, major depressive disorder, schizophrenia, essential tremor, amyotrophic lateral sclerosis, and Cushing's syndrome.

Neurocrine Biosciences, Inc. is headquartered in San Diego, California, United States. The company primarily operates in the United States but also conducts clinical trials in North America, Europe, and Asia, leveraging strategic partnerships to expand its global reach. For instance, its product INGREZZA is commercialized in Japan and other Asian markets through a partnership with Mitsubishi Tanabe Pharma Corporation.

Neurocrine Biosciences generally maintains a positive brand reputation, particularly within the healthcare and biotechnology sectors. In 2025, Forbes listed Neurocrine Biosciences among the "Most Trusted Companies in America" and "America's Best Companies," and also among the "Best Mid-Cap Companies" in 2026. Analyst ratings are predominantly positive, with a consensus "Buy" rating. No specific negative events significantly impacted Neurocrine Biosciences' brand reputation in the past year were found in the search results beyond general market concerns about potential future pricing pressure on its lead product, Ingrezza, and the inherent risks associated with pharmaceutical pipeline development.

Neurocrine Biosciences (NBIX) has a significant institutional ownership, with approximately 79.75% to 98.7% of the company's stock owned by institutional investors, including BlackRock, Inc., Vanguard Group Inc., and Dodge & Cox. Individual insiders own approximately 1.17% to 1.18% of the company's stock, while public companies and individual investors hold around 19.08% to 27.44% of the stock.